and procedures.

Who Prepares the IB?

The responsibility for preparing and maintaining the IB lies with the trial sponsor. The document is usually authored by the Medical Writing team, with inputs from:

• Nonclinical Safety and Toxicology Teams
• Clinical Development and Medical Affairs
• Regulatory Affairs
• Pharmacovigilance
• Quality Assurance

Consistency with the protocol, informed consent form (ICF), and Investigator Agreements is essential.

Standard Structure of an Investigator’s Brochure:

ICH E6(R2) Appendix 1 outlines the suggested format for the IB. Below is a structured breakdown:

1. Title Page
2. Confidentiality Statement
3. Table of Contents
4. Summary
5. Introduction
6. Physical, Chemical, and Pharmaceutical Properties
7. Nonclinical Studies
8. Effects in Humans
9. Summary of Data and Guidance for Investigator

1. Title Page and Confidentiality Statement

Include the product name, IB version number, date, sponsor name, and statement marking the document as confidential. Clearly identify the intended audience (e.g., clinical investigators).

2. Summary of Important Data

A brief, high-level summary of the investigational product’s pharmacological class, mechanism of action, safety signals, known adverse effects, and dose recommendations. This section should help investigators make informed decisions quickly.

3. Introduction

Describes the IP, the rationale for its development, and the purpose of the clinical program. It should include:

• Background of the indication
• Preclinical development summary
• Development stage and regulatory status

This section should align with the trial objectives in the protocol and the GMP manufacturing process used for the IP.

4. Physical, Chemical, and Pharmaceutical Properties

Provide detailed information about the drug substance and drug product:

• Formulation and composition
• Stability profiles including Stability Studies and expiry information
• Manufacturing process summary
• Storage conditions
• Handling precautions

Ensure compatibility with the Investigational Medicinal Product Dossier (IMPD) where applicable.

5. Nonclinical Studies

Summarize preclinical pharmacology, toxicology, genotoxicity, carcinogenicity, and reproductive toxicity studies.

• Animal model results
• NOAEL (No Observed Adverse Effect Level)
• Route-specific toxicities
• Systemic exposure comparisons

Organize data in tables where possible. Highlight any findings that may affect the trial population.

6. Effects in Humans

Present data from any prior human exposure to the product, including:

• Phase 1 results
• Pharmacokinetics (PK) and Pharmacodynamics (PD)
• Safety and tolerability
• Adverse events and dose-limiting toxicities

Use data summaries and visual tools such as exposure-response charts if available.

7. Summary of Data and Guidance for Investigator

This is the most important section from the investigator’s perspective. It should outline:

• Risk-benefit assessment
• Adverse event management
• Drug-drug interaction potential
• Contraindications and precautions
• Dosing recommendations and modifications

It helps investigators understand how to handle the IP during the trial and supports pharmaceutical validation processes for proper dosing and monitoring.

Version Control and Updates:

Include a document history log that tracks version numbers, update dates, and reasons for revision. IBs should be reviewed and updated:

• Annually (at a minimum)
• After significant new safety or efficacy data
• When the protocol or dosage is changed

Communicate updates to all stakeholders, especially investigators and ethics committees.

Tips for Writing a High-Quality IB:

1. Use clear, concise, and consistent terminology
2. Avoid excessive repetition of protocol content
3. Use visual tools (tables, charts) for quick data access
4. Incorporate cross-referencing with CRFs, ICFs, and protocol sections
5. Ensure alignment with global standards and sponsor SOPs

IB and Regulatory Submission:

The IB is often submitted as part of:

• IND submissions (Module 4 of CTD)
• Clinical Trial Applications (CTAs) in Europe
• Ethics Committee/IRB review packages

It must be signed by the sponsor and sometimes the investigator, depending on jurisdiction.

Conclusion:

The Investigator’s Brochure is more than a regulatory requirement—it is a cornerstone of trial safety and communication. Structuring it properly ensures that investigators are equipped to make informed decisions and conduct the study safely.

Following ICH guidelines, sponsor SOPs, and the step-by-step structure outlined above will help ensure clarity, compliance, and consistency across studies. A high-quality IB also builds trust with regulators, sites, and patients, setting the foundation for successful clinical development.